neuroblastoma Archives -

Shares in US biotech Y-mAbs Therapeutics have lost almost a third of their value after FDA advisors unanimously

Trial bias concern scuppers Y-mAbs brain cancer drug in FDA vote

https://pharmaphorum.com/news/trial-bias-concern-scuppers-y-mabs-brain-cancer-drug-in-fda-vote/

Y-mAbs Therapeutics has claimed its first product approval, getting a green light from the FDA for Danyelza for

Y-mAbs claims FDA OK for neuroblastoma drug Danyelza

https://pharmaphorum.com/news/y-mabs-claims-fda-ok-for-neuroblastoma-drug-danyelza/

Body makes special case due to rarity of the disease

Taking lenient stance, NICE backs neuroblastoma drug

https://pharmaphorum.com/news/taking-lenient-stance-nice-backs-neuroblastoma-drug/

Specialist company EUSA Pharma is looking for new medicines to develop after getting two cancer drugs recommended by European

EUSA Pharma looks to further in-licensing to build growth

https://pharmaphorum.com/news/uks-eusa-pharma-looks-bolster-pipeline/

Company can move in after United Therapeutics withdrew its product Unituxin

EUSA Pharma approval fills gap in neuroblastoma market

https://pharmaphorum.com/news/eusa-pharma-exploits-gap-left-united-quits-eu-neuroblastoma-market/

Unituxin too costly for use in children, NICE says.

Brain cancer drug too expensive, says NICE

https://pharmaphorum.com/news/brain-cancer-drug-too-expensive-says-nice/

neuroblastoma